Literature DB >> 30538372

Recent Strategies and Paradigm Shift in Management of Hepatic Metastasis from Colorectal Cancer.

Shekhar Gogna1, Priya Goyal2.   

Abstract

The liver is the most common site for metastasis from colorectal cancers (CRCs). There are so many new armamentarium, which have increased the life expectancy and progression-free survival. There are various available guidelines, such as NCCN, ESMO, and ASCO, which provide an insight into the latest modalities and new protocols. We have tried to elucidate into paradigm shift of the management.

Entities:  

Keywords:  Colorectal cancer; Hepatic metastasis; Multimodal treatment

Year:  2018        PMID： 30538372      PMCID： PMC6265191          DOI： 10.1007/s13193-018-0766-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  15 in total

Review 1.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

Review 2.  Ablative therapies for colorectal liver metastases: a systematic review.

Authors:  S Pathak; R Jones; J M F Tang; C Parmar; S Fenwick; H Malik; G Poston
Journal:  Colorectal Dis       Date:  2011-09       Impact factor: 3.788

3.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

4.  Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model.

Authors:  S Salah; K Watanabe; S Welter; J S Park; J W Park; J Zabaleta; F Ardissone; J Kim; M Riquet; K Nojiri; M Gisabella; S Y Kim; K Tanaka; B Al-Haj Ali
Journal:  Ann Oncol       Date:  2012-04-29       Impact factor: 32.976

5.  A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study.

Authors:  Axel Andres; Christian Toso; Rene Adam; Eduardo Barroso; Catherine Hubert; Lorenzo Capussotti; Eric Gerstel; Arnaud Roth; Pietro E Majno; Gilles Mentha
Journal:  Ann Surg       Date:  2012-11       Impact factor: 12.969

6.  Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab.

Authors:  S P Somashekhar; K R Ashwin; Shabber S Zaveri; Amit Rauthan; Poonam Patil
Journal:  Indian J Surg Oncol       Date:  2015-07-05

7.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 8.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

Authors:  R Adam
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

9.  Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients.

Authors:  Luca Viganò; Lorenzo Capussotti; Réal Lapointe; Eduardo Barroso; Catherine Hubert; Felice Giuliante; Jan N M Ijzermans; Darius F Mirza; Dominique Elias; René Adam
Journal:  Ann Surg Oncol       Date:  2013-12-18       Impact factor: 5.344

10.  Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection.

Authors:  Margo Shoup; Mithat Gonen; Michael D'Angelica; William R Jarnagin; Ronald P DeMatteo; Lawrence H Schwartz; Scott Tuorto; Leslie H Blumgart; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.